1Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamons-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial [J]. Lancet, 2003, 362 (9388):933-940.
2Dogan N, King S, Emami B, et al. Assessment of different IMRT boost delivery methods on target coverage and nor- mal-tissue sparing [J]. Int J Radiat Oncol Biol Phys, 2003, 57(5): 1480-1491.
3Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemothera- py for locally advanced oropharyngeal carcinoma [J]. Int J Radiat Oncol Biol Phys, 2006, 66(4):966-974.
4Lee NY, O'Meara W, Chan K, et al. Concurrent chemotherapy and intensity modulated radiotherapy for |o- coregionally advanced laryngeal and hypopharyngeal can- cers[J]. Int J Radiat Oncol Biol Phys, 2007,69(2):459-468.
5Schoenfeld GO, Amdur R J, Morris CG, et al. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 71(2):377-385.
6Wolden SL, Chen WC, Pfister DG, et al. Intensity-modu- lated radiation therapy(IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience [J]. Int J Radiat Oncol Biol Phys, 2006, 64(1):57-62.
7Forastiere A,Maor M, Weber R, et al. Long term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-Fu and radiationtherapy versus concurrent cisplatin and radiation therapy versus radiation therapy[J]. J Clin Oncol, 2006, 24(Suppl):abstr 5517.
8Adelstein D J, Li Y, Adams GL, et al. An intergroup phase m comparison of standard radiation therapy and two schedules of concurrent ehemoradiotherapy in patientswith unresectable squamous cell head and neck cancer[J]. J Clin Oncol, 2003, 21(1):92-98.
9Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma[J]. J Natl Cancer Inst, 2005, 97(7):536-539.
10Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus eetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between eetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1):21-28.
